Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors

Authors:

Abstract
The hepatitis B virus (HBV) infection is a crucial issue for the management of patients with hematological malignancies, who often receive treatments that suppress the immune system with a conseque...

This publication has 15 references indexed in Scilit: